Loading...
XETRSRT
Market cap14bUSD
Dec 20, Last price  
176.40EUR
1D
1.15%
1Q
-5.06%
Jan 2017
145.96%
Name

Sartorius AG

Chart & Performance

D1W1MN
XETR:SRT chart
P/E
39.85
P/S
3.97
EPS
4.43
Div Yield, %
0.73%
Shrs. gr., 5y
0.01%
Rev. gr., 5y
16.74%
Revenues
3.40b
-18.66%
467,563,000484,301,000521,053,000589,027,000611,621,000602,084,000659,317,000733,100,000845,710,000887,269,000891,168,0001,114,752,0001,300,296,0001,404,570,0001,566,034,0001,826,966,0002,335,657,0003,449,222,0004,174,700,0003,395,700,000
Net income
205m
-77.53%
15,233,00022,026,00029,019,00030,132,00016,282,000975,00031,020,00052,795,00048,510,00052,424,00048,524,000126,303,000102,932,000114,730,000141,342,000218,743,000321,472,000426,978,000913,100,000205,200,000
CFO
854m
+16.26%
50,972,00043,852,00051,715,00033,141,00052,990,000143,364,00096,008,00079,034,00053,163,000103,260,000129,688,000125,362,000170,421,000206,509,000244,524,000377,189,000511,525,000865,814,000734,200,000853,600,000
Dividend
Apr 02, 20240.73 EUR/sh
Earnings
Jan 24, 2025

Profile

Sartorius Aktiengesellschaft provides bioprocess solutions and lab products and services worldwide. The company offers biosensors and kits, compliance tools, systems software, label-free detection systems, and SPR systems; live-cell analysis systems, flow cytometry platform, and cell analysis reagents and consumables; and antibody and recombinant protein media, viral vaccines media, regenerative medicine media, general media, downstream buffer, microcarrier, and stem cell media and reagent products, as well as strong acids, bases, and alcohols and detergents. It also provides multi-parallel bioreactors, benchtop bioreactors, single-use bioreactors, stainless steel bioreactors, cell culture bioreactors, microbial bioreactors, and software apps for bioreactors; membranes, blotting products, filter papers, glass and quartz microfibre products, and filtration equipment; syringe filters; and filtration devices, ultrafiltration devices, sterile filtration devices, harvesting devices, analytical sample prep systems, buffer exchange systems, diagnostic sample prep systems, particle analysis systems, pharmaceutical filtration systems, protein DNA concentration systems, venting moisture barriers, clarification systems, buffer and media products, and membrane chromatography products. In addition, the company offers process filtration products; process filtration products; process chromatography products; fluid management products; process analytical technology and data analytics; industrial microbiology systems; water purification systems; weighing systems; pipetting and dispensing systems; OEM systems; and centrifuges. Further, it provides bioprocess development and engineering, protein expression system, media and process, testing, instrument, and validation services. It serves the life science research, biopharmaceutical manufacturing, quality control and testing, and applied industries. The company was founded in 1870 and is headquartered in Göttingen, Germany.
URL
https://www.sartorius.com/
IPO date
Apr 01, 1999
Employees
15,048
Domiciled in
DE
Incorporated in
DE

Valuation

Title
EUR in thousands, except ratios and share amounts
FYFYFYFYFYFYFYFYFYFY
2023‑122022‑122021‑122020‑122019‑122018‑122017‑122016‑122015‑122014‑12
Income
Revenues
3,395,700
-18.66%
4,174,700
21.03%
3,449,222
47.68%
Cost of revenue
2,848,100
2,985,100
2,495,897
Unusual Expense (Income)
NOPBT
547,600
1,189,600
953,325
NOPBT Margin
16.13%
28.50%
27.64%
Operating Taxes
95,900
268,600
241,445
Tax Rate
17.51%
22.58%
25.33%
NOPAT
451,700
921,000
711,880
Net income
205,200
-77.53%
913,100
113.85%
426,978
32.82%
Dividends
(98,200)
(85,900)
(48,233)
Dividend yield
0.54%
0.38%
0.14%
Proceeds from repurchase of equity
BB yield
Debt
Debt current
288,000
555,000
337,465
Long-term debt
5,170,500
2,129,800
1,853,046
Deferred revenue
Other long-term liabilities
192,100
294,100
510,531
Net debt
4,949,500
2,368,000
1,786,854
Cash flow
Cash from operating activities
853,600
734,200
865,814
CAPEX
(559,700)
(522,600)
(407,168)
Cash from investing activities
(2,823,300)
(1,129,900)
(569,608)
Cash from financing activities
2,165,700
209,900
(165,182)
FCF
(108,500)
159,840
468,492
Balance
Cash
394,200
196,800
360,985
Long term investments
114,800
120,000
42,672
Excess cash
339,215
108,065
231,196
Stockholders' equity
2,712,200
2,614,300
1,676,889
Invested Capital
7,921,585
5,111,935
3,841,798
ROIC
6.93%
20.57%
19.02%
ROCE
6.28%
21.81%
22.40%
EV
Common stock shares outstanding
68,416
68,416
68,416
Price
263.50
-21.23%
334.50
-32.70%
497.00
46.61%
Market cap
18,027,580
-21.23%
22,885,106
-32.70%
34,002,683
46.61%
EV
23,667,180
25,922,206
36,249,429
EBITDA
889,900
1,476,700
1,184,501
EV/EBITDA
26.60
17.55
30.60
Interest
185,400
35,200
26,918
Interest/NOPBT
33.86%
2.96%
2.82%